Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer

Radiation Oncology

Volumn 7, Issue 1, 2012, Pages

  Chang, Joe Y ^a   Liu, Hui ^a   Balter, Peter ^a   Komaki, Ritsuko ^a   Liao, Zhongxing ^a   Welsh, James ^a   Mehran, Reza J ^a   Roth, Jack A ^a   Swisher, Stephen G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

F fluorodeoxyglucose positron emission tomography; Non small cell lung cancer; Predictive factors; Stereotactic ablative radiotherapy; Stereotactic body radiotherapy; Toxicity

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DOSIMETRY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PNEUMONIA; PREDICTION; RADIATION DOSE FRACTIONATION; RADIATION PNEUMONIA; STEREOTACTIC ABLATIVE RADIOTHERAPY; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME; UNIVARIATE ANALYSIS; VOLUMETRY;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIATION PNEUMONITIS; RADIOSURGERY; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84865838613     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-7-152     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249. 10.3322/caac.20006, 19474385.
2. Rami-Porta R, Ball D, Crowley J, Giroux DJ, Jett J, Travis WD, Tsuboi M, Vallières E, Goldstraw P, , . International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions, International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2007, 2:593-602. 10.1097/JTO.0b013e31807a2f81, 17607114, International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions, International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions.
3. Onishi H, Araki T, Shirato H, Nagata Y, Hiraoka M, Gomi K, Yamashita T, Niibe Y, Karasawa K, Hayakawa K, Takai Y, Kimura T, Hirokawa Y, Takeda A, Ouchi A, Hareyama M, Kokubo M, Hara R, Itami J, Yamada K. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 2004, 101:1623-1631. 10.1002/cncr.20539, 15378503.
4. Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, Ewing M, Abdulrahman R, DesRosiers C, Williams M, Fletcher J. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006, 24:4833-4839. 10.1200/JCO.2006.07.5937, 17050868.
5. Nagata Y, Takayama K, Matsuo Y, Norihisa Y, Mizowaki T, Sakamoto T, Sakamoto M, Mitsumori M, Shibuya K, Araki N, Yano S, Hiraoka M. Clinical outcomes of a phase I/II study of 48Gy of stereotactic body radiation therapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys 2005, 63:1427-1431. 10.1016/j.ijrobp.2005.05.034, 16169670.
6. Chang JY, Balter PA, Dong L, Yang Q, Liao Z, Jeter M, Bucci MK, McAleer MF, Mehran RJ, Roth JA, Komaki R. Stereotactic body radiation therapy in centrally and superiorly located Stage I or isolated recurrent non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2008, 72:967-971. 10.1016/j.ijrobp.2008.08.001, 18954709.
7. Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, Fakiris A, Bezjak A, Videtic G, Johnstone D, Fowler J, Gore E, Choy H. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010, 303:1070-1076. 10.1001/jama.2010.261, 2907644, 20233825.
8. Loo BW, Chang JY, Dawson L, Kavanagh BD, Koong AC, Senan S, Timmerman RD. Stereotactic ablative radiotherapy: what's in a name?. Pract Radiat Oncol 2011, 1:38-39.
9. Lagerwaard FJ, Haasbeek CJ, Smit EF, Slotman BJ, Senan S. Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2008, 70:685-692. 10.1016/j.ijrobp.2007.10.053, 18164849.
10. Palma D, Visser O, Lagerwaard FJ, Belderbos J, Slotman BJ, Senan S. The impact of introducing stereotactic lung radiotherapy for elderly patients with stage I NSCLC: a population-based time-trend analysis. J Clin Oncol 2010, 28:5153-5159. 10.1200/JCO.2010.30.0731, 21041709.
11. Xia T, Li H, Sun Q, Wang Y, Fan N, Yu Y, Li P, Chang JY. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable stage I/II non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006, 66:117-125. 10.1016/j.ijrobp.2006.04.013, 16765528.
12. Kelly P, Balter PA, Rebueno N, Sharp HJ, Liao Z, Komaki R, Chang JY. Stereotactic body radiation therapy for patients with lung cancer previously treated with thoracic radiation. Int J Radiat Oncol Biol Phys 2010, 78:1387-1393. 10.1016/j.ijrobp.2009.09.070, 3401019, 20381271.
13. Liu H, Zhang X, Vinogradskiy YY, Swisher SG, Komaki R, Chang JY. Predicting radiation pneumonitis after stereotactic ablative radiation therapy in patients previously treated with conventional thoracic radiation therapy. Int J Radiat Oncol Biol Phys 2012, e-Pub.
14. Hoopes DJ, Tann M, Fletcher JW, Forquer JA, Lin PF, Lo SS, Timmerman RD, McGarry RC. FDG-PET and stereotactic body radiation therapy (SBRT) for stage I non-small-cell lung cancer. Lung Cancer 2007, 56:229-234. 10.1016/j.lungcan.2006.12.009, 17353064.
15. Henderson MA, Hoopes DJ, Fletcher JW, Lin PF, Tann M, Yiannoutsos CT, Williams MD, Fakiris AJ, McGarry RC, Timmerman RD. A pilot trial of serial 18-fluorodeoxyglucose positron emission tomography in patients with medical inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2010, 76:789-795. 10.1016/j.ijrobp.2009.02.051, 2823932, 19473777.
16. Burdick MJ, Stephans KL, Reddy CA, Djemil T, Srinivas SM, Videtic GM. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2010, 78:1033-1039. 10.1016/j.ijrobp.2009.09.081, 20472359.
17. Matsuo Y, Shibuya K, Nakamura M, Narabayashi M, Sakanaka K, Ueki N, Miyagi K, Norihisa Y, Mizowaki T, Nagata Y, Hiraoka M. Dose-volume metrics associated with radiation pneumonitis after stereotactic body radiation therapy for lung cancer. Int J Radiat Oncol Biol Phys 2012, 15(4):e545-e549.
18. Guckenberger M, Kestin LL, Hope AJ, Belderbos J, Werner-Wasik M, Yan D, Sonke JJ, Bissonnette JP, Wilbert J, Xiao Y, Grills IS. Is there a lower limit of pretreatment pulmonary function for safe and effective stereotactic body radiotherapy for early-stage non-small cell lung cancer?. J Thorac Oncol 2012, 7(3):542-551. 10.1097/JTO.0b013e31824165d7, 22258475.
19. Bollineni VR, Widder J, Pruim J, Langendijk JA, Wiegman EM. Residual 18F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control. Int J Radiat Oncol Biol Phys 2012, 83(4):e551-e555.
20. Chang JY, Dong L, Liu H, Starkschall G, Balter P, Mohan R, Liao Z, Cox JD, Komaki R. Image-guided radiation therapy for non-small cell lung cancer. J Thorac Oncol 2008, 3:177-186. 10.1097/JTO.0b013e3181622bdd, 18303441.
21. Welsh J, Thomas J, Shah D, Allen PK, Wei X, Mitchell K, Gao S, Balter P, Komaki R, Chang JY. Obesity increases the risk of chest wall pain from thoracic stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2011, 81:91-96. 10.1016/j.ijrobp.2010.04.022, 20542388.
22. Higashi K, Ueda Y, Arisaka Y, Sakuma T, Nambu Y, Oguchi M, Seki H, Taki S, Tonami H, Yamamoto I. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med 2002, 43:39-45.
23. Goodgame B, Pillot GA, Yang Z, Shriki J, Meyers BF, Zoole J, Gao F, Dehdashti F, Patterson A, Siegel BA, Govindan R. Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer. J Thorac Oncol 2008, 3:130-134. 10.1097/JTO.0b013e318160c122, 18303432.
24. Ohtsuka T, Nomori H, Watanabe K, Kaji M, Naruke T, Suemasu K, Uno K. Prognostic significance of [(18)F]fluorodeoxyglucose uptake on positron emission tomography in patients with pathologic stage I lung adenocarcinoma. Cancer 2006, 107:2468-2473. 10.1002/cncr.22268, 17036361.
25. Jong WK, van der Heijden HF, Pruim J, Dalesio O, Oyen WJ, Groen HJ. Prognostic value of different metabolic measurements with fluorine-18 fluorodeoxyglucose positron emission tomography in resectable non-small cell lung cancer: a two-center study. J Thorac Oncol 2007, 2:1007-1012. 10.1097/JTO.0b013e31815608f5, 17975491.
26. Zhang X, Liu H, Balter P, Allen PK, Komaki R, Pan T, Chuang HH, Chang JY. Positron Emission Tomography for Assessing Local Failure after Stereotactic Body Radiotherapy for Non-small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2012, 83(5):1558-1565. 10.1016/j.ijrobp.2011.10.035, 22572078.
27. Neri S, Takahashi Y, Terashi T, Hamakawa H, Tomii K, Katakami N, Kokubo M. Surgical treatment of local recurrence after stereotactic body radiotherapy for primary and metastatic lung cancers. J Thorac Oncol 2010, 5:2003-2007. 10.1097/JTO.0b013e3181f8a785, 21102262.
28. Barriger RB, Forquer JA, Brabham JG, Andolino DL, Shapiro RH, Henderson MA, Johnstone PA, Fakiris AJ. A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2012, 82:457-462. 10.1016/j.ijrobp.2010.08.056, 21035956.
29. Borst GR, Ishikawa M, Nijkamp J, Hauptmann M, Shirato H, Onimaru R, van den Heuvel MM, Belderbos J, Lebesque JV, Sonke JJ. Radiation pneumonitis in patients treated for malignant pulmonary lesions with hypofractionated radiation therapy. Radiother Oncol 2009, 91:307-313. 10.1016/j.radonc.2009.02.003, 19321217.
30. Guckenberger M, Baier K, Polat B, Richter A, Krieger T, Wilbert J, Mueller G, Flentje M. Dose-response relationship for radiation-induced pneumonitis after pulmonary stereotactic body radiotherapy. Radiother Oncol 2010, 97:65-70. 10.1016/j.radonc.2010.04.027, 20605245.
31. Matsuo Y, Nakamoto Y, Nagata Y, Shibuya K, Takayama K, Norihisa Y, Narabayashi M, Mizowaki T, Saga T, Higashi T, Togashi K, Hiraoka M. Characterization of FDG-PET images after stereotactic body radiation therapy for lung cancer. Radiother Oncol 2010, 97:200-204. 10.1016/j.radonc.2010.04.011, 20430463.